Miglitol oral disintegration tablet for treating diabetes II and its preparing method

The technology of oral disintegrating tablet and miglitol is applied in the field of miglitol oral disintegrating tablet for treating type II diabetes and its preparation field, which can solve the problem of drug dissolution, absorption, slow biological effect and low bioavailability , poor patient compliance, etc., to achieve the effect of reducing diabetes complications, reducing peak blood sugar concentration, and delaying absorption

Inactive Publication Date: 2005-05-18
ZHEJIANG MEDICINE CO LTD XINCHANG PHAMACEUTICAL FACTORY
View PDF0 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Film-coated tablets generally have relatively high hardness, which often leads to prolonged disintegration time, slowing down the dissolution, absorption and biological effects of the drug, resulting in reduced bioavailability; Greater risk of tissue damage leading to poor patient compliance, especially inconvenience to the elderly, children and patients with dysphagia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] formula:

[0027] Miglitol 25g

[0028] Mannitol 25g

[0029] Microcrystalline Cellulose 80g

[0030] Low-substituted hydroxypropyl cellulose 20g

[0031] Croscarmellose Sodium 25g

[0032] Micronized silica gel 1.5g

[0033] Makes 1000 pieces

[0034] Preparation process: Accurately weigh miglitol and mannitol in the formula and mix them evenly, then add micronized silica gel in the formula to increase the fluidity of the main drug, then add other excipients and mix well, then the powder is directly compressed into tablets to obtain the product.

Embodiment 2

[0036] formula:

[0037] Miglitol 50g

[0038] Mannitol 25g

[0039] Microcrystalline Cellulose 80g

[0040] Low-substituted hydroxypropyl cellulose 20g

[0041] Croscarmellose Sodium 20g

[0042] Menthol 2g

[0043] Micronized silica gel 2g

[0044] Makes 1000 pieces

[0045] Preparation process: Accurately weigh miglitol, mannitol, and menthol in the formula and mix them evenly, then add micronized silica gel in the formula to increase the fluidity of the main drug, then add other excipients and mix well, and then the powder is directly compressed into tablets. Instantly.

Embodiment 3

[0047] formula:

[0048] Miglitol 25g

[0049] Mannitol 25g

[0050] Microcrystalline Cellulose 80g

[0051] Low-substituted hydroxypropyl cellulose 20g

[0052] Croscarmellose Sodium 25g

[0053] 1.5% PVP pulp 8.5g

[0054] Magnesium Stearate 2g

[0055] Makes 1000 pieces

[0056] Preparation process: Accurately weigh and mix Miglitol and mannitol in the formula, add microcrystalline cellulose and low-substituted hydroxypropyl cellulose and mix well, add binder 1.5% PVP pulp to prepare soft material, pass Wet granules are obtained through 18-mesh sieve, dried at about 60°C for about one hour, taken out and cooled slightly, passed through 16-mesh sieve for granulation, and then added with other auxiliary materials, mixed thoroughly and then pressed into tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The orally disintegrated miglitol tablet for type-II diabetes consists of main medicine and supplementary material, the main medicine miglitol accounts for 5-50 % and is 10-200 mg in each tablet, and supplementary material consists of stuffing 5-30 wt%, disintegrating agent 5-45 wt%, disintegrating assistant 5-30 wt% and fine silica gel powder 0.1-3 wt% or consists of stuffing 5-30 wt%, disintegrating agent 5-45 wt%, disintegrating assistant 5-30 wt%, adhesive 5-15 wt% and lubricant 0.1-3 wt%. The disintegrated miglitol tablet is prepared with the material powder and through direct or wet tabletting. It is easy to take and can make full use of miglitol in treating diabetes effectively to lower the concentration of blood sugar after meal.

Description

【Technical field】 [0001] The invention relates to the field of medicine, in particular to a miglitol orally disintegrating tablet for treating type II diabetes and a preparation method thereof. 【Background technique】 [0002] Diabetes is the most common disease caused by endocrine and metabolic disorders. Diabetes is the second disease after cardiovascular disease. According to WHO survey results, there are hundreds of millions of diabetics in the world, and more than 90% of them are type II diabetics. With the improvement of people's living standards and nutritional structure, chronic non-communicable diseases such as diabetes are showing an epidemic trend. Zimmet and McCarty predict that by 2010, the number of people with diabetes worldwide will rise from 111,000,000 in 1994 to 239,000,000. The increase in the number of diabetic patients is mainly concentrated in Asia and Africa. According to relevant research estimates, the prevalence of diabetes in Asia and Africa will...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/20A61K31/445A61P3/10
Inventor 田治科侯国枝
Owner ZHEJIANG MEDICINE CO LTD XINCHANG PHAMACEUTICAL FACTORY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products